Novel Antiviral Drugs for Influenza A ID: 2013-001
Photo by starlineart - stock.adobe.com
Technology Overview
This technology encompasses 17 variants of the FDA-approved drug amantadine, specifically designed to combat the 2009 swine flu strain and potentially other strains of the influenza A virus. Developed by a collaborative team from Brigham Young University and Greek researchers, these variants have shown promising results in reducing infection rates in cultured cells, with eleven variants proving to be effective.
Key Advantages
- Targets and potentially overcomes resistance found in current influenza A strains
- Based on the FDA-approved drug amantadine, enhancing the pathway to regulatory approval
- Proven effectiveness in preclinical studies
- Collaboration between academic and research institutions ensures a robust scientific foundation
Problems Addressed
- Resistance to existing antiviral medications like amantadine and rimantadine
- Limited options for treating modern strains of influenza A virus
Market Applications
- Pharmaceuticals for the prevention and treatment of influenza A infections
- Strategic stockpiling by defense agencies for biosecurity purposes
- Potential for future adaptation to emerging influenza strains
Additional Information
Technology ID: 2013-001
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 13 May, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report